

Press Release

Daiichi Sankyo Announces Global Management Structure and Corporate Officers

Tokyo, Japan - (February 21, 2023) – Daiichi Sankyo Company, Limited today announced its Global Management Structure and appointment of Corporate Officers effective from April 1, 2023.

1. Global Management Structure

CEO•COO

Name	Current Responsibilities*	New Responsibilities
Sunao Manabe	Chief Executive Officer	Unchanged
Hiroyuki Okuzawa	Head of Corporate Planning & Management Unit, CFO	Chief Operating Officer

Global Corporate Function

Name	Current Responsibilities*	New Responsibilities
Takashi Fukuoka	Head of Corporate Strategy Unit	Head of Global Corporate Strategy
Stuart Mackey	Head of Business Development Unit	Head of Global Business Development
Koji Ogawa	—	Head of Global Corporate Planning & Management, CFO
Masahiko Ohtsuki	Head of Digital Transformation Management Unit, CIO	Head of Global DX
Takashi Matsumoto	—	Head of Global HR
Naoto Tsukaguchi	General Counsel	Head of Global Legal & IP
Naoto Tsukaguchi	General Counsel	Head of Global Compliance & Risk

Business Units

Name	Current Responsibilities*	New Responsibilities
Shoji Hirashima	Head of Japan Business Unit	Unchanged
Ken Keller	Head of Oncology Business Unit	Unchanged
Jan Van Ruymbeke	Head of EU Specialty Business Unit	Unchanged
Kiminori Nagao	Head of ASCA Business Unit	Unchanged
Paul Diolosa	Head of American Regent Unit	Unchanged
Katsuhiko Yoshida	Head of Daiichi Sankyo Healthcare Unit	Unchanged

Functional Units

Name	Current Responsibilities*	New Responsibilities
Ken Takeshita	Head of Research & Development Unit	Unchanged
Hiroto Kashiwase	Head of Supply Chain Unit	Head of Technology Unit
Toshinobu Taki	Head of Quality Assurance & Regulatory Affairs Unit	Unchanged
Kento Wada	Head of Clinical Safety & Pharmacovigilance Unit	Unchanged

Internal Audit

Name	Current Responsibilities*	New Responsibilities
Terumichi Yokoyama	—	Head of Global Internal Audit

* Responsibilities under current Global Management Structure

2. Corporate Officers (Daiichi Sankyo Company, Limited)

Name	Current Responsibilities	New Responsibilities
Sunao Manabe	Representative Director President & CEO	Representative Director Executive Chairperson & CEO
Hiroyuki Okuzawa	Director Senior Executive Officer Head of Corporate Planning & Management Div. CFO	Representative Director President & COO
Shoji Hirashima*	Representative Director Senior Executive Officer Head of Japan Business Unit	Unchanged
Masahiko Ohtsuki*	Director Senior Executive Officer Head of Digital Transformation Management Div. CIO	Director Senior Executive Officer Head of Global DX
Takashi Fukuoka*	Director Executive Officer Head of Corporate Strategy Div.	Director Executive Officer Head of Global Corporate Strategy
Wataru Takasaki	Executive Officer Head of R&D Div. & Vice President of Precision Medicine Function	Executive Officer Head of R&D Div.
Hiroto Kashiwase*	Executive Officer Head of Supply Chain Div.	Executive Officer Head of Technology Supervisory Div. & Head of Supply Chain Div.
Koji Ogawa*	Corporate Officer Head of US Corporate Div., Daiichi Sankyo, Inc.	Executive Officer Head of Global Corporate Planning & Management CFO
Takashi Matsumoto*	Corporate Officer Global Head of HR	Executive Officer Head of Global HR
Tomoji Hashiba	Corporate Officer In charge of External Affairs	Unchanged
Naoto Tsukaguchi*	Corporate Officer Vice President of Legal Affairs Dept., Corporate Affairs Div.	Corporate Officer Head of Global Legal & IP, Head of Global Compliance & Risk, Vice President of Legal Affairs Dept.
Akio Sakurai	Corporate Officer Head of Sales Div., Japan Business Unit	Corporate Officer Head of Sales & Marketing Div., Japan Business Unit
Toshinori Agatsuma	Corporate Officer Vice President of Oncology Research Laboratories I, Research Function, R&D Div.	Corporate Officer Vice President of Research Function, R&D Div.
Kiminori Nagao*	Corporate Officer Head of ASCA Business Div.	Unchanged
Nobuo Murakami	Corporate Officer Vice President of Corporate Strategy Dept., Corporate Strategy Div.	Corporate Officer Vice President of Corporate Strategy Dept., Global Corporate Strategy

Name	Current Responsibilities	New Responsibilities
Hiroshi Masumoto	Corporate Officer Vice President of Data Intelligence Dept. & Senior Director of Data Governance & Data Engineering Group, Digital Transformation Management Div.	Corporate Officer Vice President of Data Intelligence Dept., Global DX
Shizuko Ueno	Corporate Officer Head of Medical Affairs Div., Japan Business Unit	Unchanged
Akihiro Inoguchi	Corporate Officer Vice President of Development Function, R&D Div.	Unchanged
Toshi Kajiro	Corporate Officer Head of Pharmaceutical Technology Div.	Corporate Officer Head of Pharmaceutical Technology Div., Technology Supervisory Div.
Hiroya Senda	Corporate Officer Vice President of Sales Planning Dept., Sales Div., Japan Business Unit	Corporate Officer Vice President of Sales Planning Dept., Sales & Marketing Div., Japan Business Unit
Satoru Ogawa	Corporate Officer Vice President of Secretariat Dept.	Unchanged
Atsushi Tsukamoto	Corporate Officer Head of Therapeutic Area Strategies, Daiichi Sankyo, Inc.	Unchanged
Tetsuya Iwabuchi	Vice President of Business Development & Licensing Dept.	Corporate Officer In charge of Business Development
Koji Sato	Head of Global CMC Management Oncology, & DSI Pharmaceutical Technology, Daiichi Sankyo, Inc.	Corporate Officer Head of US Corporate Division, Head of Global CMC Management Oncology, & DSI Pharmaceutical Technology, Daiichi Sankyo, Inc.
Tetsuya Ohira	Vice President of Corporate Planning Dept., Corporate Planning & Management Div.	Corporate Officer Vice President of Corporate Planning Dept., Global Corporate Planning & Management
Koichi Nonaka	Vice President of Biologics Technology Research Laboratories, Biologics Div.	Corporate Officer Head of Biologics Div., Technology Supervisory Div.
Hanako Saito	Vice President of Medical Safety Dept., Clinical Safety & Pharmacovigilance Div.	Corporate Officer In charge of QARA & CSPV**
Kenji Shigeta	Vice President of Oncology Business Dept., Corporate Strategy Div.	Corporate Officer Vice President of Oncology Business Dept., Global Corporate Strategy

*Head of Corporate Function or Unit Head in Global Management Structure as of April 1, 2023

** QARA: Quality Assurance & Regulatory Affairs, CSPV: Clinical Safety & Pharmacovigilance

◇ Hironobu Furuta (current Executive Officer) will be appointed Corporate Adviser as of April 1, 2023.

◇ Masayuki Yabuta (current Executive Officer), Tohru Takahashi and Yoshinori Kaneshima (current Corporate Officer) will be appointed Senior Adviser as of April 1, 2023.

◇ Miyuki Arai (current Corporate Officer) will be in charge of Office of Audit and Supervisory Board Members as of April 1, 2023.

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical need. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit www.daiichisankyo.com.

Media Contacts:

Japan:

Koji Ogiwara
Daiichi Sankyo Co., Ltd.
ogiwara.koji.ay@daiichisankyo.co.jp
+81 3 6225 1126 (office)

Investor Relations Contact:

DaiichiSankyoIR@daiichisankyo.co.jp